{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:42:35Z","timestamp":1788302555672,"version":"build-2803163510"},"reference-count":134,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2002,5]]},"DOI":"10.1517\/14656566.3.5.575","type":"journal-article","created":{"date-parts":[[2005,5,4]],"date-time":"2005-05-04T21:25:41Z","timestamp":1115241941000},"page":"575-598","source":"Crossref","is-referenced-by-count":12,"title":["Review of enoxaparin and its clinical applications in venous and arterial thromboembolism"],"prefix":"10.1517","volume":"3","author":[{"given":"Jacqueline A","family":"Mason","sequence":"first","affiliation":[{"name":"Excerpta Medica Medical Communications, Almere, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander GG","family":"Turpie","sequence":"additional","affiliation":[{"name":"Hamilton Health Sciences, Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario, Canada, L8L 2X2, Tel: +1 905 527 1710; Fax: +1 905 521 1551;, E-mail: turpiea@mcmaster.ca"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2005,2,25]]},"reference":[{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.12968\/hosp.2000.61.9.1420"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.77.6.1213"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03540100055028"},{"issue":"4","key":"e_1_2_1_6_1","first-page":"1545","article-title":"Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and nonQ-wave myocardial infarction","volume":"89","author":"TIMI IIIB INVESTIGATORS","year":"1994","unstructured":"TIMI IIIB INVESTIGATORS: Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and nonQ-wave myocardial infarction. Results of the TIMI IIIBTrial. Thrombolysis in Myocardial Ischaemia. Circulation (1994) 89(4):1545\u20131556.","journal-title":"Results of the TIMI IIIBTrial. Thrombolysis in Myocardial Ischaemia. Circulation"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/hj.1998.v135.90302"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199856020-00013"},{"key":"e_1_2_1_9_1","unstructured":"SPENCER F LIU L ZHANG Q BALL SP BECKER RC: Enoxaparin inhibits platelet-dependent thrombin generation in vivo in patients with unstable angina and nonQ-wave myocardial infarction. J. Am. Coll. Cardiol. (1997) 29(2 Suppl. A):304A."},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018710526772"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03510140024010"},{"key":"e_1_2_1_12_1","doi-asserted-by":"crossref","unstructured":"FAREED J HOPPENSTEADT DA BICK RL: An update on heparins at the beginning of the new millennium. Semin. Thromb. Hemost. (2000) 26\\(Suppl. 1):5\u201321.","DOI":"10.1055\/s-2000-9498"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.3.251"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(99)00171-0"},{"key":"e_1_2_1_15_1","unstructured":"\u2022First study to investigate coadministration of enoxaparin with tirofiban in ACS."},{"key":"e_1_2_1_16_1","doi-asserted-by":"crossref","unstructured":"CURRIER JW POW TK HAUDENSCHILD CC MINIHAN AC FAXON DP: Low molecular weight heparin (enoxaparin) reduced restenosis following angioplasty in the hypercholesterolemic rabbit. J. Am. Coll. Cardiol. (1991) 17(6):118B-125B.","DOI":"10.1016\/0735-1097(91)90947-8"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.1.26"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.18.6.908"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1988.tb03184.x"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(85)90244-0"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1653833"},{"issue":"3","key":"e_1_2_1_22_1","first-page":"388","article-title":"Enoxaparin","volume":"49","author":"NOBLE S","year":"1995","unstructured":"NOBLE S, PETERS DH, GOA KL: Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs (1995) 49(3):388\u2013410.","journal-title":"A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800750213"},{"key":"e_1_2_1_24_1","unstructured":"\u2022\u2022First study to compare enoxaparin andUFH in prevention of VTE following general surgery"},{"key":"e_1_2_1_25_1","doi-asserted-by":"crossref","unstructured":"GEERTS WH HEIT JA CLAGETT GP et al: Prevention of venous thrombo-embolism. Chest (2001) 119:132S\u2013175S.","DOI":"10.1378\/chest.119.1_suppl.132S"},{"key":"e_1_2_1_26_1","unstructured":"SALZMAN EW HIRSH J: The epidemiology pathogenesis and natural history of venous thrombosis. In: Haemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman RW Hirsh J Marder VJ Salzman EW (Eds) Lippincott Philadelphia (1994):1275\u20131296."},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.93.1.74"},{"key":"e_1_2_1_28_1","unstructured":"PRANDONI P VILLALTA S BAGATELLA Pet al: The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica (1997) 82(4):423\u2013428."},{"key":"e_1_2_1_29_1","doi-asserted-by":"crossref","unstructured":"LEVINE MN HIRSH J GENT Met al.: Prevention of deep vein thrombosis after elective hip surgery. Ann. Intern. Med. (1991) 114(7):545\u2013551.","DOI":"10.7326\/0003-4819-114-7-545"},{"key":"e_1_2_1_30_1","unstructured":"\u2022Study showed enoxaparin to be as effective as UFH in prophylaxis of DVT in orthopedic surgery patients."},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1646980"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613894"},{"key":"e_1_2_1_33_1","unstructured":"NURMOHAMED MT VERHAEGHE R HAAS S et al.: A comparative trial of a low molecular weight heparin (enoxaparin)"},{"key":"e_1_2_1_34_1","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am. J. Surg (1995) 169:567\u2013571.","DOI":"10.1016\/S0002-9610(99)80222-0"},{"key":"e_1_2_1_35_1","first-page":"271","article-title":"Enoxaparin in the prevention of deep venous thrombosis after major surgery: multicentric study","volume":"78","author":"GAZZANIGA GM","year":"1993","unstructured":"GAZZANIGA GM, ANGELINI G, PASTORINO G, SANTORO E, LUCCHINI M, DAL PRA ML: Enoxaparin in the prevention of deep venous thrombosis after major surgery: multicentric study. The Italian Study Group. Int. Surg. (1993) 78:271\u2013275.","journal-title":"The Italian Study Group. Int. Surg."},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1002575"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800840817"},{"key":"e_1_2_1_38_1","unstructured":"\u2022\u2022Enoxaparin shown to be as effective andsafe as UFH in preventing DVT in cancer surgery patients."},{"key":"e_1_2_1_39_1","unstructured":"BERGQVIST D AGNELLI G COHEN AT ELDOR A NILSSON PE FOR THE ENOXACAN II STUDY GROUP: Prolonged prophylaxis with enoxaparin for prevention of venous thromboembolism after surgery for abdominal malignancy: the ENOXACAN II study. International Society on Thrombosis and Haemostasis. Paris France (2001)."},{"key":"e_1_2_1_40_1","unstructured":"\u2022\u2022This study shows extended enoxaparintherapy to be beneficial in cancer surgery patients."},{"key":"e_1_2_1_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198610093151503"},{"key":"e_1_2_1_42_1","doi-asserted-by":"crossref","unstructured":"COLWELL CW SPIRO TE TROWBRIDGE AA et al.: Use of enoxaparin a low-molecular-weight heparin and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. J. Bone Joint Surg Am. (1994) 76-A(1):3\u201314.","DOI":"10.2106\/00004623-199401000-00002"},{"key":"e_1_2_1_43_1","doi-asserted-by":"crossref","unstructured":"SIKORSKI JM HAMPSON WG STADDON GE et al.: The natural history and aetiology of deep vein thrombosis after total hip replacement. J. Bone Joint Surg. Br. (1981) 63-B(2):171\u2013177.","DOI":"10.1302\/0301-620X.63B2.7217137"},{"key":"e_1_2_1_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.303.6815.1431"},{"key":"e_1_2_1_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)01453-5"},{"key":"e_1_2_1_46_1","unstructured":"\u2022Prolonged prophylaxis with enoxaparin following hospital discharge was shown to be beneficial in hip replacement patients in this study."},{"key":"e_1_2_1_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199609053351002"},{"key":"e_1_2_1_48_1","doi-asserted-by":"crossref","unstructured":"FAUNO P SUOMALAINEN O REHNBERG Vet al.: Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin. J. Bone Joint Surg Am. (1994) 76-A(12):1814\u20131818.","DOI":"10.2106\/00004623-199412000-00007"},{"key":"e_1_2_1_49_1","unstructured":"SPIRO TE COLWELL CW BONA RD et al.: Enoxaparin versus unfractionated heparin for prevention of venous thromboembolic disease after knee replacement surgery. Chest (1994) 106\\(Suppl. 2):485."},{"key":"e_1_2_1_50_1","first-page":"619","volume":"124","author":"LECLERC JR","year":"1996","unstructured":"LECLERC JR, GEERTS WH, DESJARDINS Let al.: Prevention of venous thromboembolism after knee arthroplasty. A randomised, double-blind trial comparing enoxaparin with warfarin. Ann. Int. Med. (1996) 124:619\u2013626.","journal-title":"DESJARDINS Let al.: Prevention of venous thromboembolism after knee arthroplasty. A randomised, double-blind trial comparing enoxaparin with warfarin. Ann. Int. Med."},{"key":"e_1_2_1_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199412153312401"},{"key":"e_1_2_1_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199609053351003"},{"key":"e_1_2_1_53_1","unstructured":"BORRIS LC LASSEN MR POULSEN KA JENSEN HP: Thromboembolic complications after hip fracture - prophylaxis with low molecular weight versus unfractionated heparin. Thromb. Haemost. (1995) 73:1104. Abstract."},{"key":"e_1_2_1_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.50.7.609"},{"key":"e_1_2_1_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909093411103"},{"key":"e_1_2_1_56_1","unstructured":"\u2022\u2022Pivitol study showing efficacy ofenoxaparin 40 mg o.d. in prophylaxis of VTE in acutely ill medical patients."},{"key":"e_1_2_1_57_1","unstructured":"KLEBER FX WITT C FLOSBACH CW KOPPENHAGEN K VOGEL G THE PRINCE STUDY GROUP: Comparison of the low molecular weight heparin enoxaparin with unfractionated heparin in the prevention of venous thromboembolic events in medical patients with severe cardiopulmonary disease. Thromb. Haemost. (1999) 82(Suppl.):492."},{"issue":"18","key":"e_1_2_1_58_1","first-page":"I\u2013619","article-title":"Comparison of the low molecular weight heparin enoxaparin with unfractionated heparin in the prevention of venous thromboembolic events in patients with heart failure NYHA III\/IV (PRINCE II study)","volume":"100","author":"KLEBER FX","year":"1999","unstructured":"KLEBER FX, FLOSBACH CW, KOPPENHAGEN K, VOGEL G: Comparison of the low molecular weight heparin enoxaparin with unfractionated heparin in the prevention of venous thromboembolic events in patients with heart failure NYHA III\/IV (PRINCE II study). Circulation (1999) 100(18):I\u2013619.","journal-title":"Circulation"},{"key":"e_1_2_1_59_1","unstructured":"HILLBOM M ERILA T SOTANIEMI K et al.: Comparison of the efficacy and safety of the low-molecular-weight heparin enoxaparin with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. Blood (1999) (Suppl. 1):94."},{"key":"e_1_2_1_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)10265-9"},{"key":"e_1_2_1_61_1","doi-asserted-by":"crossref","unstructured":"GINSBERG JS HIRSH J: Use of antithrombotic agents during pregnancy. Chest (1998) 114:524S\u2013530S.","DOI":"10.1378\/chest.114.5_Supplement.524S"},{"key":"e_1_2_1_62_1","doi-asserted-by":"crossref","unstructured":"GINSBERG JS GREER I HIRSH J: Use of antithrombotic agents during pregnancy. Chest (2001) 119(1 Suppl.):1225\u20131315.","DOI":"10.1378\/chest.119.1_suppl.122S"},{"key":"e_1_2_1_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(94)70299-3"},{"key":"e_1_2_1_64_1","doi-asserted-by":"publisher","DOI":"10.3109\/14767050009053436"},{"key":"e_1_2_1_65_1","unstructured":"BOREL-DERLON A BORG JY BOUDIGNET O et al.: Assessment of a LMWH (enoxaparin) safety during pregnancy: a retrospective study of 624"},{"key":"e_1_2_1_66_1","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2001.117657"},{"key":"e_1_2_1_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(99)00874-7"},{"key":"e_1_2_1_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/14.11.2698"},{"key":"e_1_2_1_69_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.309.6950.299"},{"key":"e_1_2_1_70_1","unstructured":"\u2022Meta-analysis of LMWHs showing them to be effective and safe in treatment of DVT."},{"key":"e_1_2_1_71_1","doi-asserted-by":"crossref","unstructured":"LEIZOROVICZ A: Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: an updated meta-analysis. Drugs (1996) 52\\(Suppl. 7):30\u201337.","DOI":"10.2165\/00003495-199600527-00006"},{"key":"e_1_2_1_72_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430060059007"},{"key":"e_1_2_1_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)89484-3"},{"key":"e_1_2_1_74_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-10-199905180-00003"},{"key":"e_1_2_1_75_1","doi-asserted-by":"crossref","unstructured":"VAN DER HEIJDEN JF HUTTEN BA BULLER HR PRINS MH: Vitamin K antagonists or low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism. Cochrane Database Syst. Rev. (2000) 4:CD002001.","DOI":"10.1002\/14651858.CD002001"},{"key":"e_1_2_1_76_1","first-page":"677","volume":"334","author":"LEVINE M","year":"1996","unstructured":"LEVINE M, GENT M, HIRSH Jet al.: Acomparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl. J Med. (1996) 334:677\u2013681.","journal-title":"HIRSH Jet al.: Acomparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl. J Med."},{"key":"e_1_2_1_77_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-3-200102060-00009"},{"key":"e_1_2_1_78_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1993.00410130045005"},{"key":"e_1_2_1_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-198002000-00013"},{"key":"e_1_2_1_80_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-6-199703150-00006"},{"key":"e_1_2_1_81_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/54.10.1185"},{"key":"e_1_2_1_82_1","doi-asserted-by":"crossref","unstructured":"BORRIS LC LASSEN MR: Thromboprophylaxis with low molecular weight heparin after major orthopaedic surgery is cost effective. Drugs (1996) 52\\(Suppl. 7):42\u201346.","DOI":"10.2165\/00003495-199600527-00008"},{"key":"e_1_2_1_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800811212"},{"key":"e_1_2_1_84_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430070117013"},{"key":"e_1_2_1_85_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199813010-00008"},{"key":"e_1_2_1_86_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4733.2000.36005.x"},{"issue":"1","key":"e_1_2_1_87_1","first-page":"182","article-title":"A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery","volume":"20","author":"HAWKINS DW","year":"1998","unstructured":"HAWKINS DW, LANGLEY PC, KRUEGER KP: A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery. an. Then (1998) 20(1):182\u2013195.","journal-title":"an. Then"},{"key":"e_1_2_1_88_1","doi-asserted-by":"crossref","unstructured":"DEVLIN JW PETITTA A SHEPARD AD OBEID FN: Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis against venous thrombosis after major trauma. Pharmacotherapy (1998) 18(6 I):1335\u20131342.","DOI":"10.1002\/j.1875-9114.1998.tb03156.x"},{"key":"e_1_2_1_89_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200011010-00011"},{"key":"e_1_2_1_90_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4733.2000.36008.x"},{"key":"e_1_2_1_91_1","first-page":"3160","article-title":"Cost for in-patient care of venous thrombosis","volume":"160","author":"DE LISSOVOY G","year":"2000","unstructured":"DE LISSOVOY G, YUSEN RD, SPIRO TE, KRUPSKI WC, CHAMPION AH, SORENSON SV: Cost for in-patient care of venous thrombosis. A trial of enoxaparin versus standard heparin. Arch. Intern. Med. (2000) 160:3160\u20133165.","journal-title":"A trial of enoxaparin versus standard heparin. Arch. Intern. Med."},{"key":"e_1_2_1_92_1","doi-asserted-by":"crossref","unstructured":"O'BRIEN B LEVINE M WILLAN A et al.: Economic evaluation of out-patient treatment with low molecular weight heparin for proximal vein thrombosis. Arch. Intern. Med. (1999) 159(19):2298\u20132304.","DOI":"10.1001\/archinte.159.19.2298"},{"key":"e_1_2_1_93_1","unstructured":"GROCE JB: Patient outcomes and cost analysis associated with an out-patient deep venous thrombosis treatment program. Pharmacotherapy (1998) 18(6 III):175S\u2013180S."},{"key":"e_1_2_1_94_1","doi-asserted-by":"crossref","unstructured":"ARDISSINO D MERLINI PA ARIENS R COPPOLA R BRAMUCCI E MANNUCCI PM: Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet (1997) 349:769-771. 596 Expert Op\/n. Pharmacother (2002) 3(5)","DOI":"10.1016\/S0140-6736(96)11189-2"},{"key":"e_1_2_1_95_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.3.594"},{"key":"e_1_2_1_96_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.4.287"},{"key":"e_1_2_1_97_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.93.9.1634"},{"key":"e_1_2_1_98_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.90.1.61"},{"key":"e_1_2_1_99_1","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2000.2301"},{"key":"e_1_2_1_100_1","first-page":"1193","article-title":"ACC\/AHA guidelines for the management of patients with unstable angina and nonST-segment elevation myocardial infarction: executive summary and recommendations","volume":"102","author":"BRAUNWALD E","year":"2000","unstructured":"BRAUNWALD E, ANTMAN EM, BEASLEY JW et al.: ACC\/AHA guidelines for the management of patients with unstable angina and nonST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology\/ American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation (2000) 102:1193\u20131209.","journal-title":"A report of the American College of Cardiology\/ American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation"},{"key":"e_1_2_1_101_1","first-page":"61","article-title":"Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease","volume":"96","author":"KLEIN W","year":"1997","unstructured":"KLEIN W, BUCHWALD A, HILLIS SE et al.: Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragrnin in unstable coronary artery disease study (FRIG). Circulation (1997) 96:61\u201368.","journal-title":"Fragrnin in unstable coronary artery disease study (FRIG). Circulation"},{"key":"e_1_2_1_102_1","first-page":"1553","article-title":"Comparisonof two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or nonQ wave myocardial infarction: FRAX","volume":"20","author":"FRAX.I.S. STUDY GROUP","year":"1999","unstructured":"FRAX.I.S. STUDY GROUP: Comparisonof two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or nonQ wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur. Heart J. (1999) 20:1553\u20131562.","journal-title":"I.S. (FRAxiparine in Ischaemic Syndrome). Eur. Heart J."},{"key":"e_1_2_1_103_1","doi-asserted-by":"crossref","unstructured":"COHEN M DEMERS C GURFINKEL EP et al.: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl. J. Med. (1997) 337:447-452. Pivotal phase three study showing enoxaparin 1 mg\/kg b.i.d. to be more effective than UFH in preventing recurrent ischemic events in the acute treatment of UA\/NSTEMI.","DOI":"10.1056\/NEJM199708143370702"},{"key":"e_1_2_1_104_1","doi-asserted-by":"crossref","unstructured":"ANTMAN EM MCCABE CH GURFINKEL EP et al.: Enoxaparin prevents death and cardiac ischaemic events in unstable angina\/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation (1999) 100:1593\u20131601.","DOI":"10.1161\/01.CIR.100.15.1593"},{"key":"e_1_2_1_105_1","unstructured":"\u2022Confirmatory Phase III study confirming efficicy and safety of enoxaparin 1 mg\/kg b.i.d in UA\/NSTEMI treatment."},{"key":"e_1_2_1_106_1","doi-asserted-by":"crossref","unstructured":"ANTMAN EM COHEN M RADLEY D et al.: Assessment of the treatment effect of enoxaparin for unstable angina\/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation (1999) 100:1602\u20131608.","DOI":"10.1161\/01.CIR.100.15.1602"},{"issue":"3","key":"e_1_2_1_107_1","first-page":"693","article-title":"Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study","volume":"36","author":"GOODMAN SG","year":"2000","unstructured":"GOODMAN SG, COHEN M, BIGONZI F et al.: Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in nonQ Wave Coronary Events]. Am. Coll. Cardiol. (2000) 36(3):693\u2013698.","journal-title":"Efficacy and Safety of Subcutaneous Enoxaparin in nonQ Wave Coronary Events]. Am. Coll. Cardiol."},{"key":"e_1_2_1_108_1","doi-asserted-by":"crossref","unstructured":"MONTALESCOT G COLLET JP LISON Let al.: Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J. Am. Goa Cardiol. (2000) 36(1):110\u2013114.","DOI":"10.1016\/S0735-1097(00)00695-1"},{"key":"e_1_2_1_109_1","unstructured":"COHEN M THEROUX P FREY MJ et al.: Antithrombotic combination using tirofiban and enoxaparin: the ACUTE II study. Circulation (2000) 102(18)11-826. Abstract."},{"key":"e_1_2_1_110_1","unstructured":"FOX KAA ANTMAN E COHEN M BIGONZI F RADLEY D FOR THE ESSENCE\/TIMI 11B INVESTIGATORS: Are treatment effects of enoxaparin (low molecular weight heparin) more marked in those undergoing percutaneous intervention (PCI): Results of ESSENCE\/TIMI 11B. Eur. Heart J (2000) 21:599. Abstract."},{"key":"e_1_2_1_111_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.5.658"},{"key":"e_1_2_1_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)00582-2"},{"key":"e_1_2_1_113_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.90.2.908"},{"key":"e_1_2_1_114_1","doi-asserted-by":"crossref","unstructured":"ZIDAR JP: Low-molecular-weight heparins in coronary stenting (the ENTICES trial). ENoxaparin and TIClopidine after Elective Stenting. Am. J. Cardiol. (1998) 82:29L\u201332L.","DOI":"10.1016\/S0002-9149(98)00110-6"},{"key":"e_1_2_1_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01612-6"},{"key":"e_1_2_1_116_1","unstructured":"YOUNG JJ KEREIAKES DJ GRINES CL: Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. J. Invasive Cardiol. (2000) 12(Suppl. E):E14\u2013E18."},{"issue":"4","key":"e_1_2_1_117_1","first-page":"272","article-title":"Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention","volume":"13","author":"KEREIAKES DJ","year":"2001","unstructured":"KEREIAKES DJ, GRINES C, FRY E et al.: Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J. Invasive Cardiol. (2001) 13(4):272\u2013278.","journal-title":"J. Invasive Cardiol."},{"key":"e_1_2_1_118_1","unstructured":"\u2022\u2022Registry showing evidence of the safety ofenoxaparin and abciximab use during PCI."},{"key":"e_1_2_1_119_1","unstructured":"FERGUSON JJ ANTMAN EM BATES ER et al.: The use of enoxaparin and IIb\/ IIIa antagonists in acute coronary syndromes including PCI: final results of the NICE 3 study. J. Am. Goa Cardiol. (2001) 37(2 Suppl. 1):1A\u2013648A."},{"key":"e_1_2_1_120_1","unstructured":"BHATT DL LINCOFF AM FOR THE CRUISE INVESTIGATORS: Combined use of eptifibatide and enoxaparin in patients undergoing percutaneous coronary interventions: the results of the CRUISE trial. 74th Annual Meeting of the American Heart Association. Anaheim USA (2001)."},{"key":"e_1_2_1_121_1","unstructured":"GOODMAN SG: The Intergrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndromes Treatment (INTERACT). 51st Annual Session of the American College of Cardiology. Atlanta USA (21 March 2002)."},{"key":"e_1_2_1_122_1","doi-asserted-by":"publisher","DOI":"10.1161\/hc3101.093866"},{"key":"e_1_2_1_123_1","unstructured":"SIMOONS ML KRZEMINSKA-PAKULA M ALONSO A et al.: Does coronary artery patency improve with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction? Eur. Heart J In press."},{"key":"e_1_2_1_124_1","doi-asserted-by":"crossref","unstructured":"ASSENT-3 INVESTIGATORS. Efficacy and safety of tenecteplase in combination with enoxaparin abciximab or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet (2001) 358:605\u2013613.","DOI":"10.1016\/S0140-6736(01)05775-0"},{"key":"e_1_2_1_125_1","unstructured":"\u2022\u2022Large Phase II study showing the efficacyand safety of enoxaparin when used as conjunctive therapy to tenecteplase in STEMI patients."},{"key":"e_1_2_1_126_1","first-page":"1161\/01","article-title":"Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial Circulation (2002)","volume":"4","author":"ANTMAN EM","year":"2002","unstructured":"ANTMAN EM, LOUWERENBURG HW, BAARS HF et al.: Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial Circulation (2002). Published online March 4, 2002, 10.1161\/01.","journal-title":"Published online March"},{"key":"e_1_2_1_127_1","doi-asserted-by":"crossref","unstructured":"BALEN RM MARRA CA ZED PJ COHEN M FRIGHETTO L: Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes: a Canadian hospital perspective. PharmacoEconamics (1999) 16(5 II):533\u2013542.","DOI":"10.2165\/00019053-199916050-00009"},{"key":"e_1_2_1_128_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.17.1702"},{"key":"e_1_2_1_129_1","first-page":"92","article-title":"Assessing the UK cost implications of the use of low molecular weight heparin in unstable coronary artery disease","volume":"5","author":"FOX KAA, BOSANQUET N","year":"1998","unstructured":"FOX KAA, BOSANQUET N: Assessing the UK cost implications of the use of low molecular weight heparin in unstable coronary artery disease. Br. J Cardial. (1998) 5:92\u2013105.","journal-title":"Br. J Cardial."},{"key":"e_1_2_1_130_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200018010-00009"},{"key":"e_1_2_1_131_1","first-page":"15","volume":"2295","author":"LMW heparin safety alert","year":"1997","unstructured":"LMW heparin safety alert. SCRIP (1997) 2295:15.","journal-title":"SCRIP"},{"key":"e_1_2_1_132_1","unstructured":"Low molecular weight heparin boxed warning will be added to labelling; Rhone-Poulenc Rorer Lovenox reports of hematoma could apply to other LMWHs. FDC Rep Pink Sheet 1997;Dec 22:7."},{"key":"e_1_2_1_133_1","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-199710000-00031"},{"key":"e_1_2_1_134_1","doi-asserted-by":"crossref","unstructured":"SANDERINK G LELIBOUX A JARIWALA N et al.: Enoxaparin pharmacokinetics and pharmacodynarnics in renal impairment. J Am. Goa Cardial. (2001) 37(2 Suppl. A):229A.","DOI":"10.1016\/S0735-1097(01)97287-0"},{"key":"e_1_2_1_135_1","doi-asserted-by":"crossref","unstructured":"SANDERINK G LELIBOUX A JARIWALA N et al.: Enoxaparin pharmacokinetics and pharmacodynarnics in obese. J. Am. Coll. Cardial. (2001) 37(2 Suppl. A):229A.","DOI":"10.1016\/S0735-1097(01)97293-6"},{"key":"e_1_2_1_136_1","doi-asserted-by":"crossref","unstructured":"INVERSO SM COHEN M ANTMAN EM SPINLER SA: Safety and efficacy of unfractionated heparin versus enoxaparin in obese patients and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. J Am. Coll. Cardial. (2001) 37(Suppl. A):365A.","DOI":"10.1016\/S0735-1097(01)98543-2"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14656566.3.5.575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T11:18:13Z","timestamp":1770376693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14656566.3.5.575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":134,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["10.1517\/14656566.3.5.575"],"URL":"https:\/\/doi.org\/10.1517\/14656566.3.5.575","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5]]}}}